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Recent advances in cancer biology have subsequently led to the development of new molecularly
targeted anti-cancer agents that can effectively hit cancer-related proteins and pathways. Despite
better insight into genomic aberrations and diversity of cancer phenotypes, it is apparent that pro-
teomics too deserves attention in cancer research. Currently, a wide range of proteomic technolo-
gies are being used in quest for new cancer biomarkers with effective use. These, together with
newer technologies such as multiplex assays could signiﬁcantly contribute to the discovery and
development of selective and speciﬁc cancer biomarkers with diagnostic or prognostic values for
monitoring the disease state. This review attempts to illustrate recent advances in the ﬁeld of cancer
biomarkers and multifaceted approaches undertaken in combating cancer.
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a).niﬁcantly to overall morbidity and mortality. Currently there are
only limited anti-cancer therapies available with highly variable
efﬁcacy, which reﬂects an unsatisfactory cure rates. The on-set of
carcinogenesis is usually initiated with DNA alteration in the target
cell that mostly arise as a result of combination of several factors
including genetics, environmental, dietary, immune and as well
as several others still to be discovered. The DNA alterations may in-
clude a single point nucleotide exchange, deletion, ampliﬁcation,
translocation, chromosomal rearrangement, methylation or other
events that can then lead to the activation of oncogenes and inac-
tivation of tumor suppressor genes. Usually, an accumulation of
DNA alterations irreversibly transforms normal cell into dysplastic
and cancerous one. Previously, it was assumed that dysregulation
of limited amount of oncogenes or tumor-suppressor genes caused
cancers, however, more recently the alterations of many other
genes directly or indirectly involved in the carcinogenesis and tu-
mor progression process have been demonstrated. The integration
of known cancer genes into protein transduction and signalling
networks reveals their characteristic interactions within networks
and shows that cancer genes often function as ‘network hub pro-
teins’ which are involved in many cellular processes and form focal
nodes mediating cross-talk between different signalling pathways
[1–3]. Hence such disruptions in cellular communication signiﬁ-
cantly contribute to cancer development and progression. Thelsevier B.V. All rights reserved.
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by growth factors, hormones and cytokines via their receptors. In
order to understand cancers better, the roles of tyrosine kinase
receptors and signal transduction pathways such as the epidermal
growth factor receptors, platelet-derived growth factor receptors,
vascular endothelial growth factor receptors, the Ras/Raf/mito-
gen-activated protein (MAP)-kinase, phosphatidylinositol-3 kinase
(PI3K)/Akt/mammalian target of rapamycin (mTOR) and other
pathways have been studied and therapeutically targeted in differ-
ent cancers [4–6]. In 2000 Hanahan and Weinberg [7] outlined the
basic principles of a malignant process and proposed that human
cancers should demonstrate a minimal set of capabilities that are
necessary to progress to a malignant tumor state: (1) growing
uncontrollably; (2) insensitivity to anti-growth signals; (3) evading
apoptosis; (4) acquiring limitless replicative potential; (5) ability
to form and sustain new blood vessels, e.g. angiogenesis; and (6)
invasion and metastasis. The identiﬁcation of altered genes and
signalling pathways and their targets could lead to substantial
improvement in prevention, diagnosis, prognosis and tailored ther-
apy of cancers.
Recent studies have revealed that apart from the genetic abnor-
mality of many cancer-related genes/proteins, epigenetic regula-
tion of genes is also critically important in the process of
carcinogenesis. The mechanisms of epigenetic control of genes in-
volve changes of gene expression patterns mediated by modiﬁca-
tions of DNA and/or histones, without the direct alteration of
nucleotide sequence of the genes. Those modiﬁcations include sev-
eral processes, mainly the DNA methylation and the covalent mod-
iﬁcations such as acetylation, methylation, phosphorylation and
ubiquitination of speciﬁc amino acid residues of the N-termini of
the core histones [8]. Among these modiﬁcations, histone acetyla-
tion/deacetylation plays a central role in epigenetic regulation of
gene expression. Typically, high acetylation level of the chromatin
hallmarks the active transcription of the genes, whereas transcrip-
tionally inactive chromatin is usually characterised by low acetyla-
tion level of histones. It has been discovered that the occurrence of
many cancers is accompanied by a genome-wide histone hypo-
acetylation and indeed, histone deacetylase inhibitors have signif-
icant and clinically proven anti-tumor activity [9,10].
The other key question in current cancer biology is the origin
and role of cancer stem cells. Cancer stem cells are remarkably
similar to normal stem cells in respect to their ability to self-renew
and be multipotent [11–13], but until now it was not clear whether
cancer stem cells are the direct progeny of mutated stem cells or
more mature cells that re-acquire stem cell characteristics during
tumor formation. Using an inducible Cre, nuclear LacZ reporter al-
lele knocked into the Prominin1 locus (Prom1(C-L), Zhu et al. [14]
showed that Prom1(+) enterocyte precursor cells located at the
base of crypts in the small intestine represent small intestinal stem
cell. Furthermore, lineage-tracing studies of adult Prom1(+/C-L)
mice after activation of endogenous Wnt signalling pathway dem-
onstrated disruption of crypt architecture with neoplastic transfor-
mation and importantly only progeny of Prom1(+) cells retaining
Prom1 dependent reporter gene expression marked the fraction
of cells that are susceptible to neoplastic transformation. Stem cells
are typically expressing the multi-drug resistance proteins and
transporters [15]. Indeed, the cancer stem cells are capable of
resisting chemotherapy and/or radiotherapy, and they may be
responsible for failure of anti-cancer treatments. Hence, the under-
standing of cancer stem cells properties could help to eliminate
them and to prevent re-growth of cancer [16,17].
2. Anti-cancer therapies
Most of currently used conventional anti-cancer treatments
include surgery, radiotherapy and chemotherapy. Unlike ﬁrst twolocal and/or loco regional therapeutic modalities, chemotherapy
has systemic effects and it can eliminate disseminated tumor cells,
which are the ultimate reason for tumor recurrence and treatment
failure even in potentially curable stages. The chemotherapy in
oncology is focused on application of cytostatic and/or cytotoxic
drugs with potential to kill malignant cells. Such drugs may be ob-
tained using chemical synthesis or isolated and/or derivatised from
plants or different fungi and such cytotoxic and cytostatic drugs
are known to frequently induce DNA damage and/or block cellular
division. These effects are mediated via a broad spectrum of mech-
anisms and these in turn target both the tumor and rapidly prolif-
erating normal tissues. Indeed, dose of anti-cancer drugs is a
balancing act between achieving concentrations that are effective
towards the malignancy and that result in acceptable side effects.
The differences in proliferation rates, expression of speciﬁc targets
and multi-drug resistance proteins between cancer and healthy
cells together with various concentrations and metabolism of indi-
vidual cytostatic drugs in body organs or tissues are major deter-
minants of drug effects. In spite of all precautionary efforts,
frequency of secondary side effects and toxicity remains high. Neu-
tropenia is one common example of a side effect of many anti-can-
cer agents and is related to an increased risk of infection and
mortality [18]. This also reﬂects the general situation that thera-
peutic standards are based on average efﬁcacy determined by con-
trolled clinical trials involving large cohort of patients and
generally extended to the whole population. However, for many
patients, the gold standard treatment translates into very low
response rate, individual efﬁcacy is far from the mean and this
becomes evident only a few months after drug administration.
Currently approved anti-cancer drugs are sorted into several
groups according to known mechanisms inducing DNA damage
and cellular death and include: (i) alkylating cytostatic agents
(melphalan, chlorambucil, cyclophosphamide and ifosfamide,
derivatives of nitrosourea – carmustine and lomustine, busulfan,
dacarbazine, temozolomide and procarbazine); (ii) anti-metabo-
lites (methotrexate, 5-ﬂuorouracil and its derivative capecitabine,
cytosinarabinoside, gemcitabine, mercaptopurine, ﬂudarabine,
cladribine, hydroxyurea); (iii) anti-cancer antibiotics (doxorubi-
cine, idarubicine, epirubicine, mitoxantron, bleomycine, mitomy-
cin C); (iv) plant alkaloids (vinca alkaloids – vincristine,
vinblastine and vinorelbine, podofylotoxin alkaloids – etoposide
and teniposide, camptothecin analogs – topotecan and irinotecan,
taxanes – paclitaxel and docetaxel); and (v) other drugs (platinum
compounds – cisplatin, carboplatin, oxaliplatin; L-asparaginase;
amsacrin and others).
Recent advances in our understanding of cancer biology includ-
ing cancer-related genes, proteins and signalling pathways have
opened up a window for tailored and personalised anti-cancer
therapy. The ultimate goal would be tailored drug therapies using
active dosage ﬁrmly directed at speciﬁc tumors with a deﬁned
molecular proﬁle. Molecular processes in cancer cells include spe-
ciﬁc alterations in signalling pathways and protein interaction reg-
ulatory network such as over-expression and mutations of cellular
receptors and other downstream effectors. Such emerging knowl-
edge subsequently has led to the development of new molecular
targeted anti-cancer agents that hit effectively cancer-related pro-
teins and pathways. Several approaches have been applied includ-
ing inhibition of growth factor receptors and receptor tyrosine
kinases (EGFRs, VEGFR, PDGFRs, stem cell factor (SCF), c-Kit and
chimeric Bcr-Abl protein) [19–21], inhibition of intracellular effec-
tors that mediate intracellular oncogenic signaling such as Ras-
Raf- Mek-Erk MAPK or AKT (PKB) and mTOR downstream effectors
of the PI3K pathway [22], and other agents targeting integrins in-
volved in angiogenesis and invasion, selective inhibitors of histone
deacetylases, ubiquitin–proteasome system and matrix metallo-
proteinases [5,23].
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sented cytostatic activity with favorable degree of cytotoxicity as
monotherapies, only modest effects or failure in survival beneﬁt
have been observed in advanced tumors. Therefore, several strate-
gies using combination therapy have been suggested to explore
possible combination of two or more agents that may target the
same pathway more effectively or two different pathways, where
the additional one, such as angiogenesis, may complement original
target to increase treatment efﬁcacy. Other possible therapeutic
strategies include the use of molecular multi-target agents or mul-
ti-modality treatment like a combination of molecularly targeted
agents with conventional chemotherapy [24–28].
3. Impact of genomics and transcriptomics on classiﬁcation of
cancers and prediction of response to anti-cancer therapy
Today, many cancers are diagnosed and conﬁrmed by patholo-
gists. Anatomic staging plays a signiﬁcant role in making a diagno-
sis and treatment decision and classical pathological indexes such
as grading are used to make prognosis and predict development of
metastatic disease or help guide selection of a primary therapy.
However, results of recent studies have shown that the use of these
morphology-based tools is not sufﬁcient enough in accurate iden-
tiﬁcation and classiﬁcation of many different disease subtypes in
cancer patients. Several approaches are now available to detect
genomic changes leading to tumor genesis such as ﬂuorescence
in situ hybridisation, comparative genomic hybridisation and sin-
gle nucleotide polymorphism analysis including samples isolated
by laser-capture micro-dissection. Furthermore, integrating geno-
mic and transcriptomic data may signiﬁcantly enhance character-
isation of molecular ﬁngerprints associated with speciﬁc cancer
phenotypes [29–31]. Transcriptomic studies are focused on
changes in mRNA abundance and alterations in alternative splicing
[32]. Analysis of mRNA expression using cDNA microarray permits
high throughput gene expression proﬁling and represents a power-
ful screening technique allowing analysis of the activation state of
cancer-related genes and characterisation of molecular signatures
differentially expressed or spliced genes between normal and can-
cer tissue. This molecular approach has allowed the subdivision
and classiﬁcation of cancers into more homogeneous subgroups
with speciﬁc features [29,33–36]. For example Sorlie et al. [37]
identiﬁed set of 456 genes that could classify breast tumor into
molecular subtypes (luminal type A and B, Her-2/neu positive, ba-
sal-like and normal breast-like subtype) and validated these re-
sults on independent cohort of patients with locally advanced
breast cancer. They also showed that those molecular subtypes
can be clinically distinguished based on estrogen/progesterone
receptor (ER/PR) and Her-2/neu gene positivity: ER/PR positive
luminal subtypes A and B; ER+PR negative but Her-2/neu positive;
ER-PR-Her-2/neu-triple negative basal-like; and human epidermal
growth factor receptor 2 (Her-2) negative normal breast-like can-
cers. However, this study also provided additional molecular fea-
tures that did not reﬂect clinical criteria such as lymph node
stage, age and menopausal status of patients, thus underlying sig-
niﬁcant contribution of molecular transcriptional proﬁling in
objective classiﬁcation of cancers.
Despite the usefulness of microarray data in characterisation of
tumor subtypes, recent studies have focused on monitoring of anti-
cancer therapy and prediction of tumor response. The work has
been done to ascertain expression patterns for commonly used
chemotherapy like antimetabolite 5-ﬂuorouracil [38], mitotic poi-
son docetaxel [39], estrogen receptor antagonist tamoxifen [40]
and chemotherapy regimens using combined ﬂuorouracil, doxo-
rubicine and cyclophosphamide in neoadjuvant settings [41]. More
recently, this type of studies have been also extended to prediction
of therapeutic outcome in targeted anti-cancer therapies [42]. Themicroarray analysis has also been a valuable tool for demonstrat-
ing the importance of tumor milieu. Using this technology, it has
been possible to demonstrate signiﬁcant changes in expression of
cancer-related genes in cancer cells grown in a 3-D matrix as com-
pared to 2-D culture when treated with anti-cancer drugs and
compared to control untreated cells. Findings from such studies
have highlighted the importance of cellular architecture, pheno-
typic variations, and extracellular matrix barrier to drug transport
in cellular response to selected compounds. Combination of all
these parameters contributes to the overall drug efﬁcacy for that
particular cancer or tumor [43]. These studies are aimed at the dis-
covery of multigenic biomarkers with higher probability to better
describe complex biology systems. Disease and/or therapy speciﬁc
transcriptional proﬁles are followed by extensive validations in or-
der to demonstrate clinical relevance. Whilst microarray technolo-
gies are extremely useful and hold their place in research and
possibly in diagnostic arenas, there are still some associated limi-
tations that restrict their full use in the clinical environment. Once
these have been resolved, microarray technology will be at the
forefront of clinical and scientiﬁc research. Besides the obvious
technical problems associated with platform standardisation (ref-
erence RNA and housekeeping genes), reproducibility (printing
ﬂuctuation, spot variations, gene oligonucleotide tags and process-
ing), image analysis data processing (need for new bioinformatics
and biostatistical tools), there are two major caveats – essential
requirement for freshly-frozen tumor tissue or cells and lack of
knowledge on speciﬁc functions of many genes [34]. Inconvenient
sample collection, processing and storage of frozen samples for
microarray studies restrict their use for relatively small sample
sets. Additionally, the resulting classiﬁer genes require extensive
validation by other techniques including qRT-PCR or DASL (cDNA
mediated annealing, selection, extension and ligation). Indisput-
able advantage of qRT-PCR or DASL is that they can be performed
using formalin ﬁxed parafﬁn-embedded (FFPE) tumor tissue sam-
ples that present priceless source of clinical samples for investiga-
tion. The qRT-PCR utilises amplicons which are speciﬁcally
designed on DNA fragments usually less than 100 bp thus provid-
ing high efﬁciency and making it suitable for examination of gene
expression variation in ﬁxed samples containing chemically
modiﬁed and fragmented RNA. Compared to microarray analysis,
qRT-PCR is amenable to analysis of a high number of samples in
retrospective studies. The DASL assay has been developed to com-
bine the advantages of microarray and qRT-PCR technologies. As-
say allows sensitive and reproducible gene expression proﬁling
for parallel analysis of several hundreds of mRNA transcripts on
the BeadArray platform. Since this assay can be performed on FFPE
samples, this technology may be especially useful for determining
cancer prognosis or therapy response taking advantages of retro-
spective investigations of samples with known clinical outcome
[44–46].
Recent work has revealed a class of microRNAs (miRNAs), a
small non-protein coding RNAs which function as negative gene
regulators at the post-transcriptional level. miRNAs regulate multi-
ple gene targets and are capable of controlling wide range of bio-
logical processes including growth, differentiation and apoptosis.
Hence, disregulation of miRNAs may contribute to many diseases
that are known to arise from imbalance in regulation of these cel-
lular processes. It has been shown that mutations and disruption in
miRNAs biogenesis are also involved in cancer [47,48]. Studies by
Lu et al. reported express proﬁling analysis of 217 mammalian
miRNAs in 334 samples of a variety of human cancers. Expression
miRNAs proﬁles grouped tumors according to tissue of origin and
their comparison in tumor versus normal tissue reﬂected the de-
gree of cell differentiation [49]. The authors introduced a novel
bead-based ﬂow cytometric miRNA proﬁling method taking
advantage of Luminex xMAP technology where up to 100 distinct
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with a reagent speciﬁc to a particular bioassay, allowing the cap-
ture and detection of speciﬁc analytes from a sample. Within the
Luminex compact analyser, lasers excite the internal dyes that
identify each microsphere particle and also any reporter dye cap-
tured during the assay. Many readings are made on each bead
set, further validating the results. This method applied to miRNA,
couples oligonucleotides that are complementary to appropriate
miRNAs onto beads. Puriﬁed miRNAs from cell or tissue samples
are hybridised to the oligo-bound beads. Bead-based hybridisation
has the theoretical advantage that it might more closely approxi-
mate hybridisation in solution, and as such, the speciﬁcity could
be expected to be superior to chip microarray hybridisation. This
multiplex method also set the stage for future protein/nucleic acid
co-detection (http://www.luminexcorp.com/technology/index.
html). Hence this technology together with novel antibodies and
various speciﬁc biomarkers panel such as cancers, cellular sig-
nalling, cytokines, chemokines, growth factors, endocrines and
metabolic markers, represents a powerful complete solution for
‘in-depth’ studies on various cancers and other diseases.
4. Proteomics in cancer research
Despite better understanding of genomic aberrations of cancer
cells and advances in characterising diversity of cancer phenotypes
via transcriptomics, it is obvious that proteomics deserves atten-
tion in cancer research. Compared to genomic and transcriptomic
classiﬁers, proteomic features appear to be more realistic plat-
forms for identiﬁcation of cancer-related alterations in molecules
and signalling pathways and could therefore signiﬁcantly contrib-
ute to our understanding of cancerogenic developments. There are
several major reasons why one should focus on cancer proteomes:
(i) there is generally a poor correlation between transcriptional
levels of many genes and relative abundances of corresponding
proteins; (ii) due to differential splicing and translation each gene
may encode several different protein variants with different prop-
erties; (iii) the key proteins driving malignant behavior of cancer
cells can undergo post-translational modiﬁcations including phos-
phorylation and glycosylation; and (iv) proteomes are capable of
monitoring dynamic changes, hence they can be used to follow
up the course of the disease and any response to drug therapy.
However, comprehensive studies on cancer proteomes present an
important challenge and involvement of (i) extreme heterogeneity
of tissue cell populations which are part of the cancer itself or host
response to developing malignancy; (ii) broad dynamic range of
protein abundances in proximal body ﬂuids and serum/blood plas-
ma which present a rich source for biomarker identiﬁcation; and
(iii) the need for validation of molecular changes in independent
cohort of cancer patients using independent techniques and func-
tional assays. With these aspects in mind, applications of proteo-
mics to cancer research require careful consideration of currently
available or emerging novel proteomic technologies in order to
provide results that can be relevant for biological and functional
interpretation. More importantly, to move forward in the ﬁght
against cancers, the proteomic ﬁndings need to be successfully
translated into clinical oncology [50].
A variety of approaches that can be utilised in cancer proteo-
mics require proper sample preparation including sample-
enrichment strategies focused on subcellular or organelle
fractionations, phosphoproteins and glycoproteins, speciﬁc protein
tagging or tissue micro-dissection. Following proteomic analyses of
cancer tissues, cells and/or body ﬂuids are subjected to global pro-
ﬁling and/or comparative functional analysis. Protein separation-
based approaches most frequently explore gel-based techniques
(1-D and 2-D gel electrophoresis), however, gel-free liquid phase
chromatographic approaches (2-D HPLC) offer some advantagesand provide results complementary to gel-based fractionation
[51]. The major bottleneck of classical 2-DE based approach suffers
from very low dynamic range of quantiﬁcation using various stain-
ing procedures and only moderate reproducibility. The use of ﬂuo-
rescence protein labelling and running the mixture of two different
samples in one gel known as difference in gel electrophoresis
(DIGE) technique has provided researchers with improved tool to
look closer at the biomarkers of interest but did not completely
solve the problems associated with gel-based techniques as well
as protein sample complexity or high dynamic range of protein
abundances in contrast to rather low dynamic range of protein
detection and quantiﬁcation [52].
Mass spectrometry (MS) now permits the identiﬁcation of many
proteins with high sensitivity that is mostly dependent on ionisa-
tion efﬁciency of a given peptide. Sensitivity is high for puriﬁed
peptides whilst it decreases with the complexity of the samples.
Thus, the quality of protein fractionation has high impact on pro-
tein identiﬁcation coverage – in complex protein mixtures it is dif-
ﬁcult to detect low abundant peptides/proteins in the presence of
highly abundant ones. This situation is typical for many body ﬂuids
and tissues as well as detection of post-translationally modiﬁed
peptides in the presence of unmodiﬁed counterparts. At this stage,
mass spectrometry is not quantitative but allows relative compar-
ison between same peptides/proteins in a set of different samples.
MALDI-TOF (matrix assisted laser desorption ionisation-time-of-
ﬂight) is now routinely used for the identiﬁcation of proteins.
The SELDI (surface enhanced laser desorption ionisation) with
TOF mass spectrometer combines effective sample prefractiona-
tion based on capturing different types of proteins such as hydro-
phobic, hydrophilic, ionic, ligands, antibodies and others on
selective types of surfaces with mass analysis. This chip-based pro-
cedure is a relatively straightforward technology that is easily
applicable in the clinical environment. The limitation has been
the low mass accuracy which cannot be used for assignment of
protein/peptide identiﬁcations.
Hence, a need for newer technologies was highlighted for pro-
gress in the ﬁeld of cancer biomarker discovery. Modern mass
spectrometry-based quantiﬁcation methods have gained popular-
ity over the last 5 years. The determination of protein abundances
in samples is performed using stable isotope labelling techniques
including stable isotope labelling by amino acids in cell culture (SI-
LAC) or isotope-coded protein labels (ICPL) prior protein fraction-
ation. In addition, an improved approach using amine-reactive
isobaric tags for relative and absolute quantitation (iTRAQ) has
been developed with potential usefulness. This technique is based
on chemically tagging the N-terminus of peptides generated from
protein digests that have been isolated for instance from cells cul-
tured under different experimental conditions or other biological
materials [53,54]. A speciﬁc way to introduce isotope label into
peptide is the use of trypsin-catalysed incorporation of 18O during
protein digestion. The incorporated labels create speciﬁc mass tags
that can be recognised by mass spectrometry and at the same time
provide the basis for quantiﬁcation. Unlike relative quantiﬁcation,
absolute quantiﬁcation (AQUA) can be achieved using internal
standard by adding known quantity of stable isotope-labeled stan-
dard proteotypic peptide to a protein digest and subsequent com-
parison of mass spectrometric signals of standard labeled peptide
and corresponding endogenous peptide in digest. The speciﬁc
modiﬁcation of AQUA is a method called multiple reaction moni-
toring (MRM) in which the mass spectrometer monitors not only
intact peptide mass but also one or more speciﬁc fragmentations
of those peptides. The combination of retention time, peptide mass
and fragment mass eliminates ambiguities in peptide assignment
and allows for higher range of quantiﬁcation. Also, targeted frag-
mentation of selected ions allows parallel quantiﬁcation of hun-
dreds of candidate genes in the sample in very short period of
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protein enrichment by immuno-depletion or enrichment of the
peptides by antibody capture and further improvements may be
capable of extending MRMmethod to full dynamic range of plasma
proteins. With this view in mind, MRM measurement of plasma
peptide may provide a rapid and speciﬁc assay platform for high
throughput biomarker validation [55,56].
Due to problems posed by isotope labelling methods such as re-
moval of contaminating reagents, sample loss, costs and reproduc-
ibility, label-free methodologies for quantitation were introduced.
One of the label-free method is the protein microarray methodol-
ogy. Each array can contain hundreds or thousands of immobilised
proteins or antibodies, where the speciﬁcity of the protein or anti-
body, respectively, is crucial [57]. Microarrays are versatile tools
for examining large number of samples for biomarkers studies in
various environments such as drug development and clinical trials.
Protein and tissue microarray technologies provide a high-
throughput platform for protein expression investigations includ-
ing tissue sections, thus allowing analysis of several hundreds of
samples simultaneously (Fig. 1). Moreover, the advent of digital
slide technology has afforded an unparalleled opportunity for
archiving valuable histopathological and immunohistochemical
specimens. Such digital images offer a unique opportunity to pro-
vide a paradigm shift in relation to interpretation of such data via
the use of automated image analysis algorithms [58,59].
Currently, proteomic analyses have been extended to whole tis-
sue sections by using MALDI imaging. This approach allows detec-
tion of proteins in situ in the tissue sections and analysis of their
spatial distribution. Each MALDI imaging data set containing large
number of mass spectra may be evaluated using hierarchical clus-
tering that is helpful in classiﬁcation and interpretation of complex
human tissue [60].
Recently, direct tissue proteomic approach, which represents
modiﬁed shotgun proteomic tool enabling identiﬁcation of pro-
teins by micro-reverse phase LC–MS/MS isolated from FFPE tissue
was introduced [61]. The successful application of direct tissueFig. 1. Biomarker validation in tissue microarrays, example of pan anti-Akt kinase
staining using primary rabbit polyclonal antibodies (11E7, Cell Signaling, USA).proteomics needs improved extraction protocols from FFPE tissue
samples, but it offers retrospective investigation of biomarkers in
well characterised clinical samples. The combination of this tech-
nology with laser-capture micro-dissection is expected to facilitate
mapping of global signalling networks, which would be a powerful
and more informative than individual markers in diagnostics, dis-
ease prognosis and tailored cancer therapy.
5. Contribution to cancer biomarkers development
The application of a wide range of proteomic methods to the
discovery of new cancer protein biomarkers would help to identify
early markers of disease as well as help with prognosis, prediction
and monitoring of patient response to a particular therapeutic
intervention (Table 1). Such markers of disease could be released
directly by cancer cells or may represent a part of host’s response
to malignancy. These types of diagnostic candidates could be ex-
pected to be detected in body ﬂuids and hence detection is vitally
important. The cellular proteins are often shed into extracellular
ﬂuids including tissue interstitial ﬂuids and blood plasma. Whilst
tissue interstitial ﬂuids are in direct contact with tissue/cells via
transfer of molecules, the composition of blood plasma results
from the communication with tissue interstitial ﬂuids. On the
other hand, the blood plasma inﬂuences the composition of other
body ﬂuids. It is important to realise that relative concentration
of biomarkers is highest in tissue interstitial ﬂuids, which in turn
drain into lymph and lymph vessels from different tissues ﬁnally
merging and draining into the blood. As a result, the ﬁnal concen-
tration of biomarkers in blood would be signiﬁcantly lower com-
pared to interstitial ﬂuids. Hence, various body ﬂuids represent
more or less enriched source of biomarkers [62]. Application of
SELDI-TOF in the analysis of serum in a variety of cancers has been
most frequently used [63]. In order to develop a new workﬂow for
biomarker candidate identiﬁcation, Lopez et al. [64] evaluated
high-throughput carrier protein-bound afﬁnity enrichment of ser-
um samples coupled with high-resolution MALDI orthogonal TOF-
MS, discriminant analysis of the resulting mass spectral patterns,
and sequence identiﬁcation of the discriminating ions to search
for putative early protein/peptide biomarkers in ovarian cancer
serum samples. This approach yielded a number of discriminating
peptides, and provided three marker sets (9, 4, and 7 markers) that
enabled classiﬁcation of samples from cancer patients and healthy
controls. Peptide fragments associated with the coagulation cas-
cade provided the highest classiﬁcation power. Among other can-
didates were identiﬁed lower intensity peptides corresponding to
casein kinase 2, transgelin, keratin 2, glycosyl transferase (LARGE),
and diamino oxidase. The sets of the discriminating carrier-protein
bound fragments differentiated samples from patients with ovar-
ian cancer and from apparently healthy controls with sensitivities
and speciﬁcities of up to 93% and 97%, respectively. Using various
proteomic approaches, the quest for cancer biomarkers in plasma
is currently underway for particular cancers including breast, mel-
anoma, lung, and pancreatic [65,66]. Among different proteomic
technologies, serum glycomics approach is very attractive because
the glycosylation of proteins is known to change in tumor cells
during the development of cancer and these glycosylation changes
correlate with increasing tumor burden and poor prognosis. Whilst
currently used antibody-based immunochemical tests for cancer
biomarkers of ovarian (CA125), breast (CA27.29 or CA15-3), pan-
creatic, gastric, and colonic (CA19-9) carcinomas target highly gly-
cosylated mucin proteins, recent developments in MALDI-Fourier
transformation-ion cyclotron resonance (FT-ICR) MS have allowed
more detailed analysis of free glycan species resulting in glycan
proﬁles containing distinct glycan features that may correspond
to glycan ‘‘signatures of cancer” [67,68]. However, to further en-
hance the research progress it is essential to overcome limitations
Table 1
Proteomic technologies advancing cancer biomarker research.
Methodologies Technology type
with abbreviation
Research applications and usefulness Cancer research area Ref.
Gel-based methods 2-D-DIGE Diagnostic biomarkers Colorectal cancer [87]
Pancreatic adenocarcinoma [88]
Non-small-cell lung cancer [89]
Diagnostic and prognostic biomarkers Bone and soft-tissue sarcoma [90]
Bladder cancer [91]
Screening of resistance biomarkers Ovarian cancer [92,93]
Prognostic biomarkers Hepatocellular carcinoma [94]
Lung adenocarcinoma [95]
2-D-PAGE Diagnostic biomarkers Papillary thyroid cancer [96]
Prognostic biomarkers Gastrointestinal stromal tumor [71]
Mass
spectrometry-
based methods –
with isotope
labeling
iTRAQ-2-D-LC-
MS/MS
Prognostic biomarkers involved in metastatic processes Breast cancer [97]
Diagnostic and prognostic biomarkers Prostate cancer [98]
Diagnostic biomarkers Head and neck spinocellular carcinoma [99]
Hepatocellular carcinoma [100]
ICAT-MS/MS Diagnostic biomarkers in pancreatic juice Pancreatic cancer [101]
SILAC-LTQ-FT-MS/
MS
Diagnostic biomarkers Hepatocellular carcinoma [102]
SILAC-LC-MS/MS Diagnostic biomarkers Pancreatic cancer [103]
18O labeling MS Diagnostic biomarkers Cholangiocarcinoma [104]
12C6- or 13C6-NBS
labeling followed
by MALDI-QIT-
TOF
Diagnostic glycoprotein biomarkers in patient serum Lung adenocarcinoma [105]
Mass
spectrometry-
based methods -
label-free
LC–MS/MS and
MRM
Diagnostic biomarkers Mouse model of breast cancer [106]
1-D-LC/MS/MS Diagnostic biomarkers Non-small-cell lung cancer [107]
LC–MS based Prognostic biomarkers FFPE archival melanoma tissues [108]
SELDI-TOF-MS Diagnostic biomarkers in patient serum (mostly
distinguish cancer patients from healthy individuals)
Laryngeal squamous cell carcinoma [109]
Lung cancer [110]
Gastric cancer [111]
Classiﬁcations of chronic hepatitis B, liver cirrhosis and
hepatocellular carcinoma
[112]
Renal cell carcinoma [113]
Diagnostic biomarkers in pancreatic juice Malignant intraductal papillary mucinous neoplasm [114]
Diagnostic biomarkers in tissues Renal cell carcinoma [115]
Biomarkers for prediction of clinical responsiveness to
treatment
TRAIL and etoposide treated breast cancer and non-
transformed cells
[116]
MALDI imaging Diagnostic biomarkers Prostate cancer development [117]
Prostate cancer [118]
Array-based
methods
Antibody arrays Diagnostic biomarkers Esophageal adenocarcinoma [119]
Microarrays designed to detect circulating auto-
antibodies against 51 tumor-associated antigens
Helicobacter pylori infection and gastric adenocarcinoma [120]
Ovarian cancer [73]
Diagnosis and prediction of therapy response Bladder cancer [121]
Biomarkers monitoring therapeutic response Her-2 (erbB-2) oncogene-dependent breast cancer [122]
Lectin glycoarrays Diagnostic biomarkers Colorectal cancer [67]
Tissue arrays Prognostic signiﬁcance AQUA to analyze tumor-speciﬁc expression of vascular
endothelial growth factor, VEGFR-1, VEGFR-2, and
neuropilin-1 in breast cancer
[123]
Use of combined biomarkers of oncogenic HPV and tumor
suppressors of p53, pRb, and p21 in advanced TSCC
provides prognostic molecular classiﬁcation.
[124]
E2-inducible histone variant H2A.Z, is signiﬁcantly
associated with lymph node metastasis and decreased
breast cancer survival
[125]
Fluorescent-coded
bead-based
methods
LuminexxMAP
technology
Diagnostic applications in clinical labs. Technology allows
multi-analyte proﬁling with the ability to build internal
controls into the various assays and offers multi-format
and multiplexing capabilities for identifying either
genetic or protein-based markers
Search for cancer markers in various cancers, offering
great sensitivity to traditional ELISA-based systems, but
with additional advantages including extended dynamic
range and smaller sample size
[126]
Above are some examples of very recent studies utilising various proteomic technologies. More studies are recorded on Pubmed database – www.ncbi.nlm.nih.gov/pubmed/).
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Table 2
Examples of most recent studies focused on response to anti-cancer treatment.
Anti-cancer
agents
Methods Cell lines Up-regulated proteins Down-regulated proteins Ref.
Alkaloids
Etoposide + TRAIL SELDI-
TOF-MS
MDA-MB231,
ZR-75-1 and
MCF-10A
Protein S100A6, ubiquitin [116]
Vincristine 2-D-
MALDI/
TOF-MS
MCF-7 Heat shock 27 kDa protein Heat shock 27 kDa protein [80]
Vincristine 2-D-
MALDI/
TOF-MS
CEM Class I b-tubulin, Actin (fragments), lamin B1 UV excision repair protein RAD23 homolog B, 40S
ribosomal protein SA, heterogeneous nuclear
ribonucleoprotein K, heterogeneous nuclear
ribonucleoprotein F, p59 protein, ADP sugar
pyrophosphatase, 14-3-3b, 14-3-3e and 14-3-3s protein,
translationally-controlled tumor protein, L-plastin,
lamin B1, 26S proteasome, a-tubulin 1, a-tubulin 4
[127]
Alkylating agents
Temozolomid 2-D-LC/
MS
U87-MG Vimentin, RhoA 47-kDa mannose 6-phosphate receptor-binding protein [77]
Anti-cancer
antibiotics
Daunorubicin 2-D-
MALDI/
TOF-MS
EPP85-181P T-complex protein subunit a, transfer RNA-Trp-
synthetase, T-complex protein subunit b, cytokeratin19,
cytokeratin7, elongation factor 1v, heterogeneous
nuclear ribonucleoprotein, erythrocyte cytosolic
protein of 51 kDa, differentiation-related gene product,
heat shock protein 60, glucose regulated protein of
78 kDa Grp 78, heat shock 27 kDa protein
[78]
Doxorubicine 2-D-
MALDI/
TOF-MS
MCF-7 Macrophage migration inhibitory factor heat shock 27 kDa protein [79]
Antimetabolites
5-Fluorouracil 2-D-
MALDI/
TOF-MS
HeLa Glutathione-S-transferase, MAP kinase 13, amino-
methyltransferase, eukaryotic translation initiation
factor 3 subunit 3 and 4H, protein kinase C inhibitor
protein-1, heterogeneous nuclear ribonucleoproteins
C1/C2, homeobox protein BarH-like 2, ubiquitously
expressed transcript protein, cell death activator CIDE-
B, NADH-ubiquinone oxidoreductase, PDGF-associated
protein, serine–threonine protein phosphatase 2B
catalytic subunit, adenosylsuccinate synthase, acyl-
CoA dehydrogenase, telomeric repeat-binding factor 2,
histone H1.3, cation-dependent mannose-6-phosphate
receptor, Apo- 1/CD 95 (Fas), caspase-3, caspase-8, and
NADP-dependent leukotriene B4 12-hydroxy
dehydrogenase
Mitotic checkpoint protein BUB3, 60S ribosomal protein
L3, nuclear ubiquitous casein and cyclin-dependent
kinase substrate, cytohesin 3, myc proto-oncogene
protein, endoplasmic reticulum protein ERp29
precursor, translation initiation factor eIF-2B, D-b-
hydroxybutyrate dehydrogenase, protocadherin a 5
precursor, snRNA-activating protein complex 43-kDa
subunit, Src substrate cortactin, transforming protein
P21A
[128]
5-Fluorouracil +
Cisplatin
2-D-
MALDI/
TOF-MS
HeLa Cullin homolog 4B, pre-mRNA-splicing factor PRP17
(cell division cycle 40 homolog), engulfment and cell
motility protein 2, RAC-beta serine/threonine protein
kinase, TRAF family-associated NF-jB I-activator, G-
substrate, peptidyl-prolyl cis–trans isomerase E,
synaptosomalassociated protein 29, glutathione-s-
transferase, mitogen-activated protein kinase 13,
amino-methyltransferase, eukaryotic translation
initiation factor 3 subunit 3, eukaryotic translation
initiation factor 4H, protein kinase C inhibitor protein-
1, heterogeneous nuclear ribonucleoproteins C1/C2,
homeobox protein BarH-like 2, UXT protein, cell death
activator CIDE-B, NADH–ubiquinone oxidoreductase
42-kDa subunit, NADP-dependent leukotriene B4 12-
hydroxy dehydrogenase, PDGF-associated protein,
serine–threonine protein phosphatase 2B catalytic
subunit, adenylosuccinate synthetase, acyl-coA
dehydrogenase and telomeric repeat-binding factor 2
Regulator of G-protein signaling 13, ubiquitin carboxyl-
terminal hydrolase 14, mitotic spindle assembly
checkpoint protein MAD2B, 60S ribosomal protein L3,
mitotic checkpoint protein BUB3, nuclear ubiquitous
casein and cyclin-dependent kinase substrate, cytohesin
3 (ARF nucleotide-binding site opener 3), translation
initiation factor eIF-2B b subunit, myc proto-oncogene
protein, protocadherin a-5 precursor, snRNA-activating
protein complex 43-kDa subunit, D-b-hydroxybutyrate
dehydrogenase, endoplasmic reticulum protein ERp29
precursor, squamous cell carcinoma antigen 2 (leupin),
src substrate cortactin (oncogene EMS1), and
transforming protein P21A (c-K-ras).
[129]
Others:
Cisplatin 2-D-
MALDI/
TOF-MS
HeLa G-substrate, NADPH: nicotinamide adenine
dinucleotide phosphate-dependent carbonyl reductase
3, serine/threonine/tyrosine interacting protein,
cytochrome P450 4A11 precursor, regulator of G-
protein signaling 13, TRAF-interacting protein, zinc
ﬁnger protein 90, peptidyl-prolyl cis–trans isomerase
E, heterogeneous nuclear ribonucleoprotein A1,
partitioning defective-6 homolog a, prothrombin
precursor, and cyclin-dependent kinase inhibitor p27
(p27Kip1)
Tumor necrosis factor a-induced protein 3, myc proto-
oncogene, ubiquitin carboxyl-terminal hydrolase 14,
potassium voltage-gated channel subfamily G member 1
aldose reductase, mitotic spindle assembly checkpoint
protein MAD2B, Rho guanine nucleotide exchange factor
6, aldose reductase, proliferating cell nuclear antigen,
and mitochondrial processing peptidase a subunit
[130]
(continued on next page)
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Table 2 (continued)
Anti-cancer agents Methods Cell
lines
Up-regulated proteins Down-regulated proteins Ref.
Cisplatin SILAC-SDS/
PAGE-MALDI/
TOF-MS
Jurkat
T cells
Actin, adenine phosphoribosyltransferase, elongation
factor 2, eukaryotic initiation factor 4A-I, microsomal
signal peptidase 25 kDa, p21-Rac2, peroxiredoxin 1,
phosphomevalonate kinase, pre mRNA splicing factor
SRp30C, RNA-binding protein 4, tetratricopeptide
repeat domain 9C, transmembrane protein 33, tubulin
a-ubiquitous chain, tubulin b
Core-binding factor beta subunit,
heterogeneous nuclear ribonucleoprotein G,
heterogeneous nuclear ribonucleoprotein K,
heterogeneous nuclear ribonucleoprotein I,
heterogeneous nuclear ribonucleoprotein H,
heterogeneous nuclear ribonucleoproteins A2/
B1, interleukin enhancer binding factor 2,
lamina-associated polypeptide 2 isoforms b/v,
54 kDa nuclear RNA- and DNA-binding protein,
probable rRNA processing protein EBP2, Rho
GDP-dissociation inhibitor 2, spectrin a chain
[83]
Cisplatin 2-D-MALDI/TOF-
MS
A431 14-3-3 n/d and e, heat shock cognate 71 kDa protein,
tropomyosin a 3 and 4 chain, F-actin capping protein,
actin, microtubule associated protein RP/EB1, annexin
V, proteasome activator complex, 60 kDa heat shock
protein
Calmodulin, heat shock cognate 71 kDa
protein, protein disulﬁde isomerase A3,
stathmin, peroxiredoxin, peptidyl-prolyl cis–
trans isomerase
[131]
Bohemine 2-D-MALDI/TOF-
MS-ESI-MS/MS
CEM a Enolase, triosephosphate isomerase,
eucaryotic initiation factor 5A, a and b
subunits of Rho GDP-dissociation inhibitor 1
[85]
Bohemine 2-D-MALDI/TOF-
MS
A549 a-enolase, phosphoglycerate mutase, triosephosphate
isomerase, annexin I, annexin IV, actin, cytoplasmic 1,
PDZ and LIM domain protein I, endoplasmic reticulum
protein disulﬁde isomerase A3 (ER60), 60 kDa heat
shock protein, mitochondrial
Glucose-6-phosphate 1-dehydrogenase G6PD,
isomerase A3
[84]
Bohemine LC-PF2D-MALDI/
TOF-MS
CEM 60 kDa heat shock protein crk-like protein, Histone H3.3, nuclease
sensitive element binding protein 1, Histone
H2B.a,
[51]
Trichostatin A 2-D-MALDI/TOF-
MS
PaCa44 Programmed cell death protein (TFAR19), stathmin,
chromatin assembly factor 1 subunit C, growth factor
receptor bound protein 2, cytochrome c oxidase
polypeptide Vb, ARP2/3 complex 16 kDa subunit,
programmed cell death protein 5, peroxiredoxin 1,
UEV protein (ubiquitin conjugating E2 enzyme
variant), thioredoxin, hint protein, deduced protein
product shows signiﬁcant homology to coactosin
Nucleophosmin, translationally-controlled
tumor protein, 60 kDa heat shock protein,
Tropomyosin a 4 chain, calreticulin precursor,
tropomyosin a 3 chain, heterogeneous nuclear
ribonucleoproteins A2/B1, glyceraldehyde 3-
phosphate dehydrogenase, ATP synthase beta-
chain, 60S acidic ribosomal protein PO
[132]
Gemcitabine + Trichostatin
A
2-D-PAGE-
MALDI/TOF and
Q/TOF-MS
T3M4 [133]
Trichostatin A S100A11 protein, peroxiredoxin I, guanine nucleotide-
binding protein b subunit-like protein
Stress 70 protein mitochondrial
Gemcitabine S100A11 protein, peroxiredoxin I Stress 70 protein mitochondrial, tubulin b
chain
Trichostatin
A + Gemcitabine
Peroxiredoxin I, superoxide dismutase, thioredoxin,
glutathione-S-transferase, 14-3-3 protein a, stathmin
heat shock protein HSP 90-alpha, stress 70
protein mitochondrial, cytokeratin type II CK8
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prove knowledge about cancer tissue and its secretome.
The identiﬁcation of new diagnostic or prognostic biomarkers
characterising risk of cancer development and/or tumor progres-
sion or drug targets is mostly based on direct analysis of cancer
cells and tissues and often utilises some of the above described
proteomic methods. Large-scale proteomic analysis of 64 human
ovarian cancer tissue samples presenting benign, borderline and
malignant stages based on histological evaluation was performed
using DIGE with each sample run in duplicate. Evaluation of pro-
tein quantitative data using non-supervised clustering distin-
guished between normal and malignant tissue samples,
however, application of supervised methods allowed objective
classiﬁcation into four groups – normal ovaries, benign, border-
line and malignant. Additionally, protein spot changes signiﬁ-
cantly contributing to this classiﬁcation were reported to
represent potential diagnostic tumor markers. Among those can-
didates, cytokeratin 19-type1, ErbB3, prohibitin, adenylosuccinate
lyase and integrin alpha-5 were veriﬁed via tissue microarrays
and others are currently under development to be tested for diag-
nostic purposes in tissue as well as blood samples [69]. Applica-
tion of DIGE with large format of 2-D electrophoretic separation
for laser microdissected tissue was utilised by group of Kondo
[70] to investigate proteomic signatures of several types of malig-
nancies including lung, pancreatic, colorectal, hepatocellular andcholangiocellular carcinomas, malignant mesotheliomas and
soft-tissue sarcomas. Interestingly, they identiﬁed 43 protein
spots whose intensity was statistically different between gastro-
inestinal stromal tumor (GIST) with good and poor prognosis.
Mass spectrometric protein identiﬁcation showed eight of the
43 spots derived from pfetin, a potassium channel protein, and
four of the eight pfetin spots had a high discriminative power be-
tween the two groups. Western blotting and real-time PCR
showed that pfetin expression and tumor metastasis were inver-
sely related. The prognostic performance of pfetin was also exam-
ined by immunohistochemistry on 210 GIST cases. The 5-year
metastasis-free survival rate was 93.9% versus 36.2% for patients
with pfetin-positive versus pfetin-negative tumors, respectively
(P < 0.0001). Univariate and multivariate analyses revealed that
pfetin expression was a powerful prognostic factor among the
clinicopathologic variables examined, including risk classiﬁcation
and c-kit- or platelet-derived growth factor receptor A mutation
status. These results may also provide novel therapeutic strate-
gies to prevent metastasis of GIST [71].
To obtain new insight into cancer cell invasion and migration,
multidimensional protein identiﬁcation technology (MudPIT) has
been used in six established ovarian cancer cell lines. Within whole
cell extracts MudPIT identiﬁed proteins that mapped to 2245 un-
ique genes. Unsupervised cluster analysis partitioned the cell lines
in amanner that reﬂected their motile/invasive capacity. A compar-
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low motile/invasive capacity revealed 300 proteins that were dif-
ferentially expressed, of which 196 proteins were signiﬁcantly
up-regulated in group with high invasive capacity. Western blot
analysis for selected proteins conﬁrmed the expression proﬁles
revealed by MudPIT, demonstrating the ﬁdelity of this high-
throughput analysis. Protein network modeling indicated a func-
tional interplay between proteins up-regulated in group of high
motile/invasive capacity cell lines characterised and increased
expression of several key members of the actin cytoskeleton,
extracellular matrix and focal adhesion pathways. These proteo-
mic expression proﬁles could prove to be essential in the devel-
opment of more effective strategies that target pivotal cell
signalling pathways used by cancer cells during local invasion
and distant metastasis [72].
Many cancer patients produce antibodies against tumor-associ-
ated antigens. The humoral immune response represents a form of
biological ampliﬁcation of signals that are otherwise weak because
of very low concentrations of antigen, especially in the early stages.
Hence, it is interesting to employ protein microarrays to identify
these antigens. In one typical study, protein microarrays contain-
ing 5005 human proteins and auto-antibodies from 30 cancer pa-
tients were used to identify proteins that are aberrantly
expressed in ovarian tissue. The differential reactivity of four anti-
gens was tested by using immunoblot analysis and tissue micro-
arrays. Lamin A/C, structure speciﬁc recognition protein 1
(SSRP1), and Ral binding protein 1 (RALBP1) were found to exhibit
increased expression in the cancer tissue relative to controls. The
combined signals from multiple antigens proved to be a robust test
to identify malignant ovarian tissue and proteins aberrantly ex-
pressed in different disease states [73].6. Focus on prediction of efﬁcacy and monitoring of anti-cancer
therapies
Clinical importance of biomarkers suitable for monitoring ther-
apeutic response is of growing importance. Assessment of an indi-
vidual patient and tumor predisposition to drugs is prerequisite to
successful application of targeted anti-cancer therapy. This ap-
proach is needed namely for clinicians to stratify the patients
and make proper decision about chemotherapeutic drugs that
would be most effective and with minimal side effects. It is ex-
pected that proteomic proﬁling will help to answer the questions
of tumor drug sensitivity/resistance and knowledge of molecular
mechanisms that underly cancer drug response would signiﬁcantly
contribute to achieving this aim. In order to predict cancer drug re-
sponse by proteomic proﬁling, Ma et al. [74] used reverse-phase
protein microarrays covering 60 human cancer cell lines (NCI-60
panel) to measure protein expression levels by 52 antibodies. The
speciﬁcity of each of the antibodies was veriﬁed by Western blot-
ting. The NCI-60 panel contains 2–9 cell lines per each histological
tumor type including leukemias, melanomas, and carcinomas of
ovaries, renal, breast, prostate, colon, lung and central nervous sys-
tem [75]. The drug activities of 118 agents were measured by
growth inhibition within 48 h. In order to establish the classiﬁers
that would be independent of tissue of origin, a combination of
several algorithms were used. The results showed that it was fea-
sible to used this data set (60 cell lines  52 targets  118 drugs) to
generate signiﬁcant chemosensitivity classiﬁers for 118 evaluated
agents with statistical signiﬁcance level P < 0.02. The range of drug
responses was classiﬁed into three categories: sensitive, resistant
and intermediate. It is important to stress, that this type of proteo-
mic studies are focused on prediction of response without any
analyses of molecular mechanisms underlying response to the
drug.The era of chemotherapy began in 1940s with the ﬁrst uses of
nitrogen mustards, which are nonspeciﬁc DNA alkylating agents,
and later antifolates. In the early 1950s other anti-tumor drugs like
anti-metabolites and vinca alkaloids came into clinical trials and
use. In 1955 began systematic drug screening at the National Can-
cer Institute and new screening approach based on use of 60 cell
lines derived from different human cancer types was introduced
in 1989 [76]. The following are examples of several recent studies
focused on more detail proteomic analyses of response to selected
conventional chemotherapeutic drugs. The effect of alkylating
agent temozolomide alone or in combination with radiotherapy
on the protein expression proﬁle of human U87-MG glioma cells
in vitro was investigated by Trog et al. [77]. Using comparative
analysis of protein expression pattern they found upregulation of
vimentin, an extracellular matrix component, induced by temozol-
omide treatment. Interestingly, vimentin contributes to the mech-
anism of tumor progression supporting its pro-invasive and pro-
angiogenic activity. Hence, potential molecular target, which in
fact contributes to expansion of the cancer is promoted by treated
glioma cells. This ﬁnding demonstrates usefulness of proteomic
studies for uncovering possible mechanisms that interfere with
successful therapy. Anti-cancer antibiotics are known to cause
DNA damage (intercalation into DNA bases, interference with
DNA unwinding via inhibition of topoisomerases I and/or II) and
to affect tumor cell growth. 2-D gel electrophoresis was used to
investigate the response of pancreatic tumor cells after exposure
to daunorubicin. Identiﬁed up-regulated proteins after drug expo-
sure participate in a variety of cellular processes probably due to
activation of various signalling pathways in response to daunoru-
bicin [78]. Human breast tumor cell line MCF-7 was used to inves-
tigate protein proﬁle changes after doxorubicin treatment. Three
isoforms of heat shock 27 kDa protein (HSP27) were found to be
signiﬁcantly decreased [79]. Interestingly, in investigation per-
formed by Casado et al. [80] cellular response to plant vinca alka-
loid vincristine on MCF7 cells also revealed vincristine dependent
regulation of speciﬁc isoforms of anti-apoptotic protein HSP27.
Since there was no effect on HSP27 mRNA they suggested that vin-
cristine was implicated in the protein post-translational modiﬁca-
tion with up-regulation of Ser 82 phosphorylation. However, such
data should be interpreted carefully, as HSP27 is highly abundant
protein and it is one of the most frequently responsive protein mol-
ecules in human samples [81].
The use of combination of conventional chemotherapeutic
agent vinblastine with targeted agent rapamycin (mTOR inhibi-
tor) was studied at the protein level on the EA.hy926 endothelial
cell line using 2-D gel electrophoresis coupled to MALDI mass
spectrometry protein identiﬁcation. Some of the regulated pro-
teins were involved in the processes of angiogenesis, prolifera-
tion, migration and apoptosis. The authors veriﬁed proteomic
data for several proteins using Western blots and also applied
the computer modelling for generating a network of molecules
that have common function and share similar target pathways
to show that observed protein changes merged into synergistic
antiangiogenic activity of vinblastine and rapamycin [82]. Plati-
num cytostatics belong to the group of potent and clinically
important metal-based anti-cancer drugs. One of the most recent
studies concerning molecular effects of cisplatin on cancer cells
was published by Schmidt et al. [83]. The authors performed
quantitative analysis of protein changes after cisplatin-induced
apoptosis in Jurkat T cells to identify proteins related to the
mechanism of cisplatin function. SILAC was used for quantitative
proteome analysis of control versus apoptotic cells after cisplatin
treatment. The time point for full activation of apoptosis was
chosen for experiments. It was interesting that 8 of 26 identiﬁed
apoptosis-related proteins contained at least one RNA-binding
motif.
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inhibitor (CDKI) as a promising anti-cancer drug. We applied com-
plementary proteomic approaches to analyse responses of CEM T-
lymphoblastic leukemia and A549 lung adenocarcinoma lines as
representatives of haematological malignancy and solid tumor,
respectively. Based on the evaluation of the protein maps and pos-
sible pathways relevant to responses to CDKI, the glycolytic en-
zymes, annexin IV and the crkl adaptor protein appear to be
important targets. Collectively, our proteomic ﬁndings underline
the importance of cell cycle control in both the cellular signaling
and metabolic pathways. Initial conﬁrmation studies focused di-
rectly on the crkl protein have proved the validity of the proteomic
results, but the potential utility of CDKI warrants further study and
validation using different types of tumor models [51,84,85].
The analysis of known cell signalling networks or pathways for
a patient can be currently obtained from a biopsy specimen of
given individual using reverse-phase protein microarrays. In
this approach, the entire cellular proteome is immobilised and sub-
sequent immunodetection reveals phosphorylation status of sig-
nalling proteins. Therefore it is suitable for monitoring of
multiple pharmacodynamic biomarkers of response to molecular
targeted agents. Boyd et al. [86] applied this protocol to examine
phosphorylation status of 100 proteins in a panel of 30 breast can-
cer cell lines and showed distinct pathways activation in different
subtypes that were not obvious from previous gene expression
studies. It was shown that inhibitors of epidermal growth factor
receptor and mitogen-activated protein kinase/extracellular sig-
nal-regulated kinase result in compensatory up-regulation of the
phosphatidylinositol-3-kinase/Akt signalling pathway indicating
that combined inhibition of both pathways should translate into
synergistic tumor killing.
Many of the above mentioned studies were followed up at var-
ious time interval when apoptotic process occur. However, more
interesting and speciﬁc would be the characterisation of earlier
protein changes that precede the on-set of apoptosis. More studies
on the molecular mechanisms underlying the effect of individual
conventional, targeted and developmental chemotherapeutics, or
their combinations are urgently needed. In fact, the number of
publications covering this issue is low (Table 2). Furthermore,
monitoring molecular mechanisms in earlier time intervals after
drug exposure may be beneﬁcial for detecting relevant proteins
that are responsible for primary changes in signalling networks
and subsequently lead later to irreversible anti-cancer processes
including cell division cycle block, induction of apoptosis, and
interference with cancer-related angiogenesis, invasion and
metastasis.
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